NovAccess Global Inc. (XSNX)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.03 Million USD | -5.93% |
| 2022 | - USD | 13.2% |
| 2021 | - USD | 54.66% |
| 2020 | -6.96 Million USD | -2946.83% |
| 2019 | -544.11 Thousand USD | 202.89% |
| 2018 | -202.01 Thousand USD | -181.84% |
| 2017 | -71.67 Thousand USD | 65.25% |
| 2016 | -137.49 Thousand USD | 13.94% |
| 2015 | -1.07 Million USD | 42.62% |
| 2014 | -1.17 Million USD | 56.45% |
| 2013 | -957.99 Thousand USD | -24.83% |
| 2012 | -1.25 Million USD | 37.49% |
| 2011 | -1.03 Million USD | 30.32% |
| 2010 | -2.07 Million USD | -162.87% |
| 2009 | -10.5 Million USD | 169.56% |
| 2008 | -3.8 Million USD | -10.09% |
| 2007 | -1.82 Million USD | -11.65% |
| 2006 | -3.28 Million USD | -140.38% |
| 2005 | -1.36 Million USD | 11.78% |
| 2004 | -1.54 Million USD | -960.83% |
| 2003 | -145.84 Thousand USD | -208.36% |
| 2002 | -47.29 Thousand USD | 86.66% |
| 2001 | -354.53 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -232.56 Thousand USD | -116.91% |
| 2024 Q1 | -257.55 Thousand USD | 194.03% |
| 2024 Q3 | -936.33 Thousand USD | -222.76% |
| 2023 FY | - USD | -5.93% |
| 2023 Q1 | -517.12 Thousand USD | 58.78% |
| 2023 Q4 | -430.76 Thousand USD | 11.12% |
| 2023 Q3 | -484.64 Thousand USD | 54.06% |
| 2023 Q2 | -1.05 Million USD | -104.01% |
| 2022 Q4 | -1.25 Million USD | -286.09% |
| 2022 Q1 | -322.32 Thousand USD | 35.54% |
| 2022 Q2 | -426.94 Thousand USD | -32.46% |
| 2022 Q3 | -324.91 Thousand USD | 23.9% |
| 2022 FY | - USD | 13.2% |
| 2021 Q4 | -500.01 Thousand USD | 0.29% |
| 2021 Q1 | -1.39 Million USD | 72.91% |
| 2021 Q3 | -501.49 Thousand USD | -78.26% |
| 2021 FY | - USD | 54.66% |
| 2021 Q2 | -281.32 Thousand USD | 79.9% |
| 2020 FY | - USD | -2946.83% |
| 2020 Q3 | -489.87 Thousand USD | -562.83% |
| 2020 Q2 | 105.84 Thousand USD | 236.75% |
| 2020 Q1 | -77.39 Thousand USD | -167.25% |
| 2020 Q4 | -5.16 Million USD | -954.71% |
| 2019 FY | - USD | 202.89% |
| 2019 Q1 | -22.32 Thousand USD | 44.55% |
| 2019 Q2 | 132.93 Thousand USD | 695.55% |
| 2019 Q3 | -17.83 Thousand USD | -113.42% |
| 2019 Q4 | 115.08 Thousand USD | 745.15% |
| 2018 Q3 | -10.3 Thousand USD | 85.4% |
| 2018 Q4 | -40.25 Thousand USD | -290.82% |
| 2018 Q1 | -80.88 Thousand USD | -14.64% |
| 2018 Q2 | -70.57 Thousand USD | 12.75% |
| 2018 FY | - USD | -181.84% |
| 2017 Q4 | -70.55 Thousand USD | -142.69% |
| 2017 FY | - USD | 65.25% |
| 2017 Q3 | -29.07 Thousand USD | -148.27% |
| 2017 Q2 | 60.22 Thousand USD | 286.62% |
| 2017 Q1 | -32.27 Thousand USD | 46.3% |
| 2016 Q2 | 40.68 Thousand USD | 150.73% |
| 2016 Q1 | -80.19 Thousand USD | -434.85% |
| 2016 Q3 | -106.65 Thousand USD | -362.13% |
| 2016 Q4 | -60.09 Thousand USD | 43.65% |
| 2016 FY | - USD | 13.94% |
| 2015 FY | - USD | 42.62% |
| 2015 Q4 | 23.94 Thousand USD | 151.34% |
| 2015 Q3 | -46.65 Thousand USD | 32.05% |
| 2015 Q2 | -68.65 Thousand USD | 25.58% |
| 2015 Q1 | -92.25 Thousand USD | -145.86% |
| 2014 Q4 | 201.17 Thousand USD | 346.62% |
| 2014 Q1 | -377.45 Thousand USD | 24.41% |
| 2014 FY | - USD | 56.45% |
| 2014 Q2 | -159.77 Thousand USD | 57.67% |
| 2014 Q3 | -81.57 Thousand USD | 48.94% |
| 2013 FY | - USD | -24.83% |
| 2013 Q4 | -499.33 Thousand USD | -258.78% |
| 2013 Q3 | -139.17 Thousand USD | 21.13% |
| 2013 Q2 | -176.47 Thousand USD | -335.51% |
| 2013 Q1 | 74.93 Thousand USD | 110.39% |
| 2012 Q4 | -721.42 Thousand USD | -698.42% |
| 2012 FY | - USD | 37.49% |
| 2012 Q3 | 120.55 Thousand USD | 197.48% |
| 2012 Q2 | -123.66 Thousand USD | -183.1% |
| 2012 Q1 | -43.68 Thousand USD | 49.72% |
| 2011 Q3 | -302.5 Thousand USD | 36.18% |
| 2011 Q1 | -365.59 Thousand USD | 41.92% |
| 2011 Q2 | -473.97 Thousand USD | -29.65% |
| 2011 Q4 | -86.87 Thousand USD | 71.28% |
| 2011 FY | - USD | 30.32% |
| 2010 FY | - USD | -162.87% |
| 2010 Q2 | -481.04 Thousand USD | 5.36% |
| 2010 Q3 | -144.78 Thousand USD | 69.9% |
| 2010 Q1 | -508.27 Thousand USD | -163.94% |
| 2010 Q4 | -629.45 Thousand USD | -334.74% |
| 2009 Q2 | -1.21 Million USD | -1.27% |
| 2009 Q4 | 794.89 Thousand USD | -82.12% |
| 2009 Q3 | 4.44 Million USD | 466.11% |
| 2009 Q1 | -1.19 Million USD | -74.31% |
| 2009 FY | - USD | 169.56% |
| 2008 Q4 | -687.92 Thousand USD | 3.55% |
| 2008 Q3 | -713.27 Thousand USD | 2.5% |
| 2008 Q2 | -731.6 Thousand USD | 61.31% |
| 2008 Q1 | -1.89 Million USD | -100.86% |
| 2008 FY | - USD | -10.09% |
| 2007 Q2 | -482.18 Thousand USD | 18.2% |
| 2007 Q3 | -549.97 Thousand USD | -14.06% |
| 2007 Q4 | -941.39 Thousand USD | -71.17% |
| 2007 FY | - USD | -11.65% |
| 2007 Q1 | -589.45 Thousand USD | 49.57% |
| 2006 Q3 | -290.36 Thousand USD | 20.32% |
| 2006 Q4 | -1.16 Million USD | -302.54% |
| 2006 Q2 | -364.43 Thousand USD | 76.61% |
| 2006 Q1 | -1.55 Million USD | -113.18% |
| 2006 FY | - USD | -140.38% |
| 2005 Q1 | -164.89 Thousand USD | 87.31% |
| 2005 Q2 | -205.64 Thousand USD | -24.71% |
| 2005 Q3 | -282.37 Thousand USD | -37.31% |
| 2005 FY | - USD | 11.78% |
| 2005 Q4 | -731.01 Thousand USD | -158.88% |
| 2004 Q4 | -1.29 Million USD | -965.15% |
| 2004 Q3 | -122.02 Thousand USD | -89.34% |
| 2004 Q2 | -64.44 Thousand USD | -54.79% |
| 2004 Q1 | -41.63 Thousand USD | 68.31% |
| 2004 FY | - USD | -960.83% |
| 2003 Q4 | -131.4 Thousand USD | -896.51% |
| 2003 FY | - USD | -208.36% |
| 2003 Q2 | - USD | 100.0% |
| 2003 Q1 | -1259.00 USD | 95.35% |
| 2003 Q3 | -13.18 Thousand USD | 0.0% |
| 2002 Q4 | -27.08 Thousand USD | -4610.09% |
| 2002 Q1 | -2545.00 USD | 63.58% |
| 2002 Q3 | -575.00 USD | 96.64% |
| 2002 FY | - USD | 86.66% |
| 2002 Q2 | -17.09 Thousand USD | -571.67% |
| 2001 Q3 | -6501.00 USD | -477.35% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | -6987.00 USD | -7.48% |
| 2001 Q2 | -1126.00 USD | 41.14% |
| 2001 Q1 | -1913.00 USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 98.543% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 82.547% |
| SQZ Biotechnologies Company | -64.14 Million USD | 98.387% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 94.043% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.1% |
| Mesoblast Limited | -62.38 Million USD | 98.341% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 32.633% |
| Genus plc | 73.7 Million USD | 101.404% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 84.349% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 70.826% |
| Marizyme, Inc. | -34.28 Million USD | 96.981% |
| ContraFect Corporation | -64.99 Million USD | 98.408% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 88.203% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 77.138% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 26.181% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 60.869% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 55.47% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -99.75% |
| Accustem Sciences Inc. | -3.74 Million USD | 72.379% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 97.854% |
| EV Biologics, Inc. | -1.26 Million USD | 18.336% |
| Q BioMed Inc. | -617.62 Thousand USD | -67.544% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 128.97% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -63.629% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 54.703% |
| Biomind Labs Inc. | -1.03 Million USD | -0.024% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 110.477% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 85.55% |
| Skye Bioscience, Inc. | -13.54 Million USD | 92.362% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 30.43% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -4039.188% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 73.36% |
| IMV Inc. | -35.52 Million USD | 97.087% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 93.479% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 58.641% |
| GB Sciences, Inc. | -1.41 Million USD | 27.121% |
| Alpha Cognition Inc. | -9.7 Million USD | 89.338% |
| HST Global, Inc. | -5303.00 USD | -19413.426% |
| CSL Limited | 4.78 Billion USD | 100.022% |
| Halberd Corporation | -74.27 Thousand USD | -1293.122% |
| Enzolytics Inc. | -2.12 Million USD | 51.235% |
| Resverlogix Corp. | -11.74 Million USD | 91.187% |
| Affymax, Inc. | -14.29 Million USD | 92.761% |
| SYBLEU INC | -141.57 Thousand USD | -630.939% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 66.216% |
| argenx SE | -216.02 Million USD | 99.521% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 98.13% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 185.029% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 30.963% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 373.146% |
| AVAX Technologies, Inc. | -6.11 Million USD | 83.071% |
| Zenith Capital Corp. | -8.6 Million USD | 87.976% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.584% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -5839.94% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 57.702% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -487.871% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 97.389% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 64.223% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 1.101% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 15489.604% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 40.869% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 46.13% |
| BioStem Technologies, Inc. | -7.55 Million USD | 86.301% |
| ONE Bio Corp. | 13.61 Million USD | 107.602% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -471.433% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 49.694% |
| Agentix Corp. | -1.37 Million USD | 24.564% |
| LadRx Corporation | 412.28 Thousand USD | 350.992% |
| Cell Source, Inc. | -4.27 Million USD | 75.78% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -181.791% |
| Regen BioPharma, Inc. | 1.46 Million USD | 170.589% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -10.443% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 111.688% |
| Itoco Inc. | -1.86 Million USD | 44.634% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -172.588% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 7.276% |
| Kadimastem Ltd | -2.62 Million USD | 60.57% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -332.698% |
| CytoDyn Inc. | -18.02 Million USD | 94.26% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1209.389% |
| Mobile Lads Corp. | -2.24 Million USD | 53.828% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -8361.828% |
| Qrons Inc. | -40.08 Thousand USD | -2481.764% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -113.062% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 296.195% |
| Rebus Holdings, Inc. | -951 Thousand USD | -8.811% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 2.562% |
| International Stem Cell Corporation | 202 Thousand USD | 612.276% |
| Bioxytran, Inc. | -3.82 Million USD | 72.912% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -1865.8% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 57.968% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 97.115% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -2199.549% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 62.206% |
| Neutra Corp. | -181.24 Thousand USD | -470.932% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 94.867% |
| PureTech Health plc | -11.62 Million USD | 91.1% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 94.866% |
| IXICO plc | -707 Thousand USD | -46.364% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 86.535% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 97.86% |
| CSL Limited | 4.73 Billion USD | 100.022% |
| Cellectis S.A. | -92.63 Million USD | 98.883% |